Synopsis
Synopsis
0
CEP/COS
0
JDMF
0
KDMF
0
VMF
0
FDF
0
Europe
0
Canada
0
South Africa
0
Listed Dossiers
DRUG PRODUCT COMPOSITIONS
0
US Patents
0
US Exclusivities
0
Health Canada Patents
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
Annual Reports
NA
Finished Drug Prices
NA
1. Dibenylene
2. Dibenyline
3. Dibenziran
4. Dibenzylin
5. Dibenzyline
6. Dibenzyran
7. Hydrochloride, Phenoxybenzamine
8. Phenoxybenzamine
1. 63-92-3
2. Phenoxybenzamine Hcl
3. Dibenzyline
4. N-benzyl-n-(2-chloroethyl)-1-phenoxypropan-2-amine Hydrochloride
5. Dibenzyline Hydrochloride
6. Dibenzyran
7. Dibenzyline Chloride
8. Phenoxybenzamine Chloride
9. Phenoxybenzamine (hydrochloride)
10. Bensylyt Nen
11. Dibenzylin
12. Phenoxybenzamine.hcl
13. Nci-c01661
14. Nsc-37448
15. 2-(n-benzyl-2-chloroethylamino)-1-phenoxypropane Hydrochloride
16. N-(2-chloroethyl)-n-(1-methyl-2-phenoxyethyl)benzylamine Hydrochloride
17. Mls000069374
18. Chebi:8078
19. Nsc 37448
20. 63-92-3 (hcl)
21. Smr000058422
22. N-benzyl-n-(2-chloroethyl)-1-phenoxypropan-2-amine;hydrochloride
23. Dsstox_cid_1127
24. N-(2-chloroethyl)-n-(1-methyl-2-phenoxyethyl)benzenemethanamine Hydrochloride
25. Benzenemethanamine, N-(2-chloroethyl)-n-(1-methyl-2-phenoxyethyl)-,hydrochloride
26. Dsstox_rid_75958
27. Dsstox_gsid_21127
28. N-2-phenoxyisopropyl-n-benzyl-chloroethylamine Hydrochloride
29. Benzyl(2-chloroethyl)(1-methyl-2-phenoxyethyl)amine Hydrochloride
30. X1ieg24ohl
31. Benzylamine, N-(2-chloroethyl)-n-(1-methyl-2-phenoxyethyl)-, Hydrochloride
32. Benzenemethanamine, N-(2-chloroethyl)-n-(1-methyl-2-phenoxyethyl)-, Hydrochloride
33. Phenoxybenzamine Hydrochloride (usp)
34. Sr-01000000017
35. Dibenzylene
36. Dibenzyline (tn)
37. Mfcd00055152
38. Pob Hcl
39. Cpd000058422
40. Opera_id_300
41. Cas-63-92-3
42. Phenoxybenzaminehydrochloride
43. Schembl50729
44. Bensylyte Hydrochloride
45. Mls002222313
46. Spectrum2300176
47. Chembl1200787
48. Dtxsid0021127
49. Hy-b0431a
50. Hms1570n10
51. Pharmakon1600-02300176
52. Phenoxybenzamine Hydrochloride,(s)
53. Bcp28467
54. Nsc37448
55. Tox21_201588
56. Tox21_302978
57. Wln: G2n1r&y1&1or &gh
58. Ccg-39614
59. Nsc759572
60. Akos015966790
61. Ac-8077
62. Lp00235
63. Nc00598
64. Nsc-759572
65. Ncgc00089748-02
66. Ncgc00089748-06
67. Ncgc00093699-01
68. Ncgc00093699-02
69. Ncgc00093699-03
70. Ncgc00093699-04
71. Ncgc00256370-01
72. Ncgc00259137-01
73. As-16927
74. Phenoxybenzamine Hydrochloride [mi]
75. Db-054579
76. B-019
77. D0158
78. Eu-0100235
79. Ft-0603264
80. Ft-0673569
81. Ft-0673570
82. N-benzyl-n-(2-chloroethyl)-1-phenoxypropan
83. Phenoxybenzamine Hydrochloride [iarc]
84. Phenoxybenzamine Hydrochloride [vandf]
85. S2499
86. Sw197327-3
87. En300-52514
88. Phenoxybenzamine Hydrochloride [mart.]
89. C07436
90. D00507
91. Phenoxybenzamine Hydrochloride [usp-rs]
92. Phenoxybenzamine Hydrochloride [who-dd]
93. Phenoxybenzamine Hydrochloride, >=97%, Powder
94. 055p152
95. J-009731
96. Phenoxybenzamine Hydrochloride [orange Book]
97. Sr-01000000017-2
98. Sr-01000000017-6
99. Phenoxybenzamine Hydrochloride [usp Monograph]
100. Q27107723
101. N-benzyl-n-(2-chloroethyl)-1-phenoxypropan-2-amine;hydron;chloride
102. N-(2-chloroethyl)-n-(1-methyl-2-phenoxyethyl)benzylamine, Hydrochloride
103. N-2-phenoxyisopropyl-n-benzyl-.beta.-chloroethylamine Hydrochloride
104. Benzenemethanamine, N-(2-chloroethyl)-n-(1-methyl-2-phenoxyethyl)-, Hydrochloride (1:1)
105. Benzenemethanamine, N-(2-chloroethyl)-n-(1-methyl-2-phenoxyethyl)-,hcl
106. Phenoxybenzamine Hydrochloride, United States Pharmacopeia (usp) Reference Standard
107. 34238-85-2
108. Phenoxybenzamine Hcl Pound>>nci-c01661 Pound>> Nci C01661 Pound>> Ncic01661 Pound>>nsc 37448 Pound>>nsc37448 Pound>>nsc-37448
109. Phenoxybenzamine Hydrochloride, Pharmaceutical Secondary Standard; Certified Reference Material
Molecular Weight | 340.3 g/mol |
---|---|
Molecular Formula | C18H23Cl2NO |
Hydrogen Bond Donor Count | 1 |
Hydrogen Bond Acceptor Count | 2 |
Rotatable Bond Count | 8 |
Exact Mass | 339.1156697 g/mol |
Monoisotopic Mass | 339.1156697 g/mol |
Topological Polar Surface Area | 12.5 Ų |
Heavy Atom Count | 22 |
Formal Charge | 0 |
Complexity | 262 |
Isotope Atom Count | 0 |
Defined Atom Stereocenter Count | 0 |
Undefined Atom Stereocenter Count | 1 |
Defined Bond Stereocenter Count | 0 |
Undefined Bond Stereocenter Count | 0 |
Covalently Bonded Unit Count | 2 |
1 of 4 | |
---|---|
Drug Name | Dibenzyline |
Drug Label | Each Dibenzyline capsule, with red cap and body, is imprinted WPC 001 and 10 mg, and contains 10 mg of Phenoxybenzamine Hydrochloride USP. Inactive ingredients consist of D&C Red No. 33, FD&C Red No. 3, FD&C Yellow No. 6, Gelatin NF, Lactose N |
Active Ingredient | Phenoxybenzamine hydrochloride |
Dosage Form | Capsule |
Route | Oral |
Strength | 10mg |
Market Status | Prescription |
Company | Wellspring Pharm |
2 of 4 | |
---|---|
Drug Name | Phenoxybenzamine hydrochloride |
PubMed Health | Phenoxybenzamine (By mouth) |
Drug Classes | Cardiovascular Agent |
Drug Label | Each Dibenzyline capsule, with red cap and body, is imprinted WPC 001 and 10 mg, and contains 10 mg of Phenoxybenzamine Hydrochloride USP. Inactive ingredients consist of D&C Red No. 33, FD&C Red No. 3, FD&C Yellow No. 6, Gelatin NF, Lactose N |
Active Ingredient | Phenoxybenzamine hydrochloride |
Dosage Form | Capsule |
Route | Oral |
Strength | 10mg |
Market Status | Prescription |
Company | Roxane |
3 of 4 | |
---|---|
Drug Name | Phenoxybenzamine hydrochloride |
PubMed Health | Phenoxybenzamine (By mouth) |
Drug Classes | Cardiovascular Agent |
Drug Label | Each Dibenzyline capsule, with red cap and body, is imprinted WPC 001 and 10 mg, and contains 10 mg of Phenoxybenzamine Hydrochloride USP. Inactive ingredients consist of D&C Red No. 33, FD&C Red No. 3, FD&C Yellow No. 6, Gelatin NF, Lactose N |
Active Ingredient | Phenoxybenzamine hydrochloride |
Dosage Form | Capsule |
Route | Oral |
Strength | 10mg |
Market Status | Prescription |
Company | Roxane |
4 of 4 | |
---|---|
Drug Name | Dibenzyline |
Drug Label | Each Dibenzyline capsule, with red cap and body, is imprinted WPC 001 and 10 mg, and contains 10 mg of Phenoxybenzamine Hydrochloride USP. Inactive ingredients consist of D&C Red No. 33, FD&C Red No. 3, FD&C Yellow No. 6, Gelatin NF, Lactose N |
Active Ingredient | Phenoxybenzamine hydrochloride |
Dosage Form | Capsule |
Route | Oral |
Strength | 10mg |
Market Status | Prescription |
Company | Wellspring Pharm |
Adrenergic alpha-Antagonists
Drugs that bind to but do not activate alpha-adrenergic receptors thereby blocking the actions of endogenous or exogenous adrenergic agonists. Adrenergic alpha-antagonists are used in the treatment of hypertension, vasospasm, peripheral vascular disease, shock, and pheochromocytoma. (See all compounds classified as Adrenergic alpha-Antagonists.)
Antihypertensive Agents
Drugs used in the treatment of acute or chronic vascular HYPERTENSION regardless of pharmacological mechanism. Among the antihypertensive agents are DIURETICS; (especially DIURETICS, THIAZIDE); ADRENERGIC BETA-ANTAGONISTS; ADRENERGIC ALPHA-ANTAGONISTS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; CALCIUM CHANNEL BLOCKERS; GANGLIONIC BLOCKERS; and VASODILATOR AGENTS. (See all compounds classified as Antihypertensive Agents.)
Vasodilator Agents
Drugs used to cause dilation of the blood vessels. (See all compounds classified as Vasodilator Agents.)
Nuray is an expert in the synthesis of Niche novel APIs, the first to launch Generics, NCEs, Advanced Intermediates // USFDA certified.
GDUFA
DMF Review : Reviewed
Rev. Date : 2018-03-29
Pay. Date : 2018-01-12
DMF Number : 32443
Submission : 2018-01-25
Status : Active
Type : II
Date of Issue : 2024-02-20
Valid Till : 2026-12-06
Written Confirmation Number : WC-0416
Address of the Firm :
NDC Package Code : 58159-044
Start Marketing Date : 2022-10-04
End Marketing Date : 2024-12-31
Dosage Form (Strength) : POWDER (35kg/35kg)
Marketing Category : BULK INGREDIENT
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 25580
Submission : 2012-01-11
Status : Active
Type : II
GDUFA
DMF Review : Reviewed
Rev. Date : 2019-02-11
Pay. Date : 2019-01-28
DMF Number : 33477
Submission : 2018-12-27
Status : Active
Type : II
NDC Package Code : 59651-298
Start Marketing Date : 2024-01-10
End Marketing Date : 2025-12-31
Dosage Form (Strength) : POWDER (50kg/50kg)
Marketing Category : BULK INGREDIENT
GDUFA
DMF Review : Reviewed
Rev. Date : 2019-08-16
Pay. Date : 2020-03-05
DMF Number : 31746
Submission : 2017-12-28
Status : Active
Type : II
NDC Package Code : 76339-143
Start Marketing Date : 2019-09-06
End Marketing Date : 2025-12-31
Dosage Form (Strength) : POWDER (4.999kg/4.999kg)
Marketing Category : BULK INGREDIENT
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 20011
Submission : 2006-11-29
Status : Active
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 4264
Submission : 1981-09-04
Status : Inactive
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 16593
Submission : 2003-05-13
Status : Inactive
Type : II
NDC Package Code : 47621-309
Start Marketing Date : 2019-09-17
End Marketing Date : 2025-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT
Related Excipient Companies
Excipients by Applications
Global Sales Information
Market Place
REF. STANDARDS & IMPURITIES
ABOUT THIS PAGE
A Phenoxybenzamine HCl manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Phenoxybenzamine HCl, including repackagers and relabelers. The FDA regulates Phenoxybenzamine HCl manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Phenoxybenzamine HCl API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
click here to find a list of Phenoxybenzamine HCl manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.
A Phenoxybenzamine HCl supplier is an individual or a company that provides Phenoxybenzamine HCl active pharmaceutical ingredient (API) or Phenoxybenzamine HCl finished formulations upon request. The Phenoxybenzamine HCl suppliers may include Phenoxybenzamine HCl API manufacturers, exporters, distributors and traders.
click here to find a list of Phenoxybenzamine HCl suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
A Phenoxybenzamine HCl DMF (Drug Master File) is a document detailing the whole manufacturing process of Phenoxybenzamine HCl active pharmaceutical ingredient (API) in detail. Different forms of Phenoxybenzamine HCl DMFs exist exist since differing nations have different regulations, such as Phenoxybenzamine HCl USDMF, ASMF (EDMF), JDMF, CDMF, etc.
A Phenoxybenzamine HCl DMF submitted to regulatory agencies in the US is known as a USDMF. Phenoxybenzamine HCl USDMF includes data on Phenoxybenzamine HCl's chemical properties, information on the facilities and procedures used, and details about packaging and storage. The Phenoxybenzamine HCl USDMF is kept confidential to protect the manufacturer’s intellectual property.
click here to find a list of Phenoxybenzamine HCl suppliers with USDMF on PharmaCompass.
A Phenoxybenzamine HCl written confirmation (Phenoxybenzamine HCl WC) is an official document issued by a regulatory agency to a Phenoxybenzamine HCl manufacturer, verifying that the manufacturing facility of a Phenoxybenzamine HCl active pharmaceutical ingredient (API) adheres to the Good Manufacturing Practices (GMP) regulations of the importing country. When exporting Phenoxybenzamine HCl APIs or Phenoxybenzamine HCl finished pharmaceutical products to another nation, regulatory agencies frequently require a Phenoxybenzamine HCl WC (written confirmation) as part of the regulatory process.
click here to find a list of Phenoxybenzamine HCl suppliers with Written Confirmation (WC) on PharmaCompass.
National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing Phenoxybenzamine HCl as an active pharmaceutical ingredient (API).
The FDA updates the NDC directory daily. The NDC numbers for Phenoxybenzamine HCl API and other APIs are published in this directory by the FDA.
The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.
Pharmaceutical companies that manufacture Phenoxybenzamine HCl as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.
The NDC directory also contains data on finished compounded human drug products that contain Phenoxybenzamine HCl and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a Phenoxybenzamine HCl NDC to their finished compounded human drug products, they may choose to do so.
click here to find a list of Phenoxybenzamine HCl suppliers with NDC on PharmaCompass.
Phenoxybenzamine HCl Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Phenoxybenzamine HCl GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Phenoxybenzamine HCl GMP manufacturer or Phenoxybenzamine HCl GMP API supplier for your needs.
A Phenoxybenzamine HCl CoA (Certificate of Analysis) is a formal document that attests to Phenoxybenzamine HCl's compliance with Phenoxybenzamine HCl specifications and serves as a tool for batch-level quality control.
Phenoxybenzamine HCl CoA mostly includes findings from lab analyses of a specific batch. For each Phenoxybenzamine HCl CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Phenoxybenzamine HCl may be tested according to a variety of international standards, such as European Pharmacopoeia (Phenoxybenzamine HCl EP), Phenoxybenzamine HCl JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Phenoxybenzamine HCl USP).
LOOKING FOR A SUPPLIER?